A group of hospital systems are using the machine-learning model to guide decisions on who should be tested for high levels of lipoprotein(a).
The firm is discontinuing its CHIRON and THETIS trials after lackluster data and is planning for potential third-party deals and workforce layoffs.
The agency reviewed data from the MARIPOSA-2 trial and approved the regimen for patients with common EGFR mutations who are progressing on EGFR inhibitors.